End-of-day quote
Shenzhen S.E.
23:00:00 25/06/2024 BST
|
5-day change
|
1st Jan Change
|
19.3
CNY
|
+2.82%
|
|
-3.31%
|
-33.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39,247
|
94,292
|
106,395
|
76,952
|
47,371
|
31,138
|
-
|
-
|
Enterprise Value (EV)
1 |
35,694
|
92,214
|
107,852
|
80,810
|
51,092
|
34,496
|
34,273
|
33,470
|
P/E ratio
|
62.2
x
|
81.5
x
|
68.8
x
|
58.6
x
|
32.1
x
|
20.2
x
|
16.9
x
|
15.2
x
|
Yield
|
0.29%
|
0.25%
|
0.32%
|
0.44%
|
0.69%
|
1.12%
|
1.24%
|
1.2%
|
Capitalization / Revenue
|
10.4
x
|
18.4
x
|
14.3
x
|
7.5
x
|
4.11
x
|
2.44
x
|
2.15
x
|
1.9
x
|
EV / Revenue
|
9.5
x
|
18
x
|
14.5
x
|
7.87
x
|
4.43
x
|
2.71
x
|
2.37
x
|
2.04
x
|
EV / EBITDA
|
37.5
x
|
54.5
x
|
45
x
|
34.8
x
|
18.7
x
|
11
x
|
9.55
x
|
8.17
x
|
EV / FCF
|
190
x
|
274
x
|
-3,252
x
|
-101
x
|
-540
x
|
-363
x
|
31.3
x
|
13.6
x
|
FCF Yield
|
0.53%
|
0.36%
|
-0.03%
|
-0.99%
|
-0.19%
|
-0.28%
|
3.19%
|
7.37%
|
Price to Book
|
5.27
x
|
10.8
x
|
11.1
x
|
7.83
x
|
4.12
x
|
2.49
x
|
2.2
x
|
1.94
x
|
Nbr of stocks (in thousands)
|
1,787,372
|
1,787,372
|
1,786,898
|
1,786,601
|
1,786,732
|
1,780,556
|
-
|
-
|
Reference price
2 |
22.91
|
53.51
|
62.79
|
45.33
|
28.98
|
19.30
|
19.30
|
19.30
|
Announcement Date
|
28/02/20
|
28/03/21
|
10/03/22
|
30/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3,757
|
5,134
|
7,444
|
10,266
|
11,538
|
12,747
|
14,455
|
16,421
|
EBITDA
1 |
951.3
|
1,692
|
2,399
|
2,321
|
2,730
|
3,123
|
3,590
|
4,096
|
EBIT
1 |
652.2
|
874.8
|
1,914
|
1,690
|
1,722
|
1,950
|
2,285
|
2,631
|
Operating Margin
|
17.36%
|
17.04%
|
25.72%
|
16.46%
|
14.92%
|
15.3%
|
15.81%
|
16.02%
|
Earnings before Tax (EBT)
1 |
632.6
|
1,319
|
1,911
|
1,666
|
1,838
|
1,846
|
2,179
|
2,556
|
Net income
1 |
547.2
|
1,172
|
1,661
|
1,375
|
1,601
|
1,622
|
1,938
|
2,221
|
Net margin
|
14.56%
|
22.84%
|
22.31%
|
13.39%
|
13.88%
|
12.72%
|
13.41%
|
13.53%
|
EPS
2 |
0.3681
|
0.6569
|
0.9128
|
0.7739
|
0.9019
|
0.9573
|
1.142
|
1.269
|
Free Cash Flow
1 |
187.4
|
336
|
-33.17
|
-803.9
|
-94.53
|
-95
|
1,095
|
2,468
|
FCF margin
|
4.99%
|
6.54%
|
-0.45%
|
-7.83%
|
-0.82%
|
-0.75%
|
7.57%
|
15.03%
|
FCF Conversion (EBITDA)
|
19.7%
|
19.86%
|
-
|
-
|
-
|
-
|
30.49%
|
60.25%
|
FCF Conversion (Net income)
|
34.25%
|
28.66%
|
-
|
-
|
-
|
-
|
56.48%
|
111.12%
|
Dividend per Share
2 |
0.0667
|
0.1333
|
0.2000
|
0.2000
|
0.2000
|
0.2156
|
0.2397
|
0.2312
|
Announcement Date
|
28/02/20
|
28/03/21
|
10/03/22
|
30/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q4
|
2021 S2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2,121
|
2,193
|
2,940
|
3,286
|
2,142
|
4,158
|
4,635
|
-
|
2,863
|
5,632
|
2,724
|
2,916
|
5,640
|
2,920
|
2,978
|
5,898
|
2,671
|
3,196
|
5,761
|
3,316
|
3,534
|
6,820
|
3,239
|
3,379
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
677.9
|
708.3
|
1,245
|
760.3
|
510.1
|
414.9
|
925
|
431.6
|
482.3
|
913.9
|
414.6
|
424.2
|
838.8
|
268.4
|
466
|
775
|
520.1
|
579.4
|
1,092
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
20.63%
|
33.06%
|
29.93%
|
16.4%
|
-
|
14.49%
|
16.42%
|
15.84%
|
16.54%
|
16.2%
|
14.2%
|
14.25%
|
14.22%
|
10.05%
|
14.58%
|
13.45%
|
15.68%
|
16.39%
|
16.01%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
708.4
|
1,245
|
-
|
464.8
|
458.9
|
-
|
426.6
|
481.9
|
908.5
|
412.4
|
516.9
|
929.4
|
-
|
497
|
765
|
485
|
613
|
1,098
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
564.8
|
621
|
1,096
|
-
|
375.7
|
413.5
|
-
|
348.3
|
437.8
|
786.1
|
352.9
|
462.1
|
815
|
-
|
420
|
635
|
415
|
553
|
968
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
17.19%
|
28.99%
|
26.36%
|
-
|
-
|
14.44%
|
-
|
12.78%
|
15.01%
|
13.94%
|
12.09%
|
15.52%
|
13.82%
|
-
|
13.14%
|
11.02%
|
12.51%
|
15.65%
|
14.19%
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.2000
|
0.2598
|
-
|
-
|
-
|
-
|
-
|
0.3200
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/20
|
26/08/20
|
28/03/21
|
29/08/21
|
10/03/22
|
10/03/22
|
29/08/22
|
27/10/22
|
30/03/23
|
30/03/23
|
27/04/23
|
27/08/23
|
27/08/23
|
29/10/23
|
27/03/24
|
27/03/24
|
25/04/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
1,457
|
3,859
|
3,721
|
3,359
|
3,136
|
2,332
|
Net Cash position
1 |
3,553
|
2,077
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.6074
x
|
1.663
x
|
1.363
x
|
1.076
x
|
0.8735
x
|
0.5695
x
|
Free Cash Flow
1 |
187
|
336
|
-33.2
|
-804
|
-94.5
|
-95
|
1,095
|
2,468
|
ROE (net income / shareholders' equity)
|
10.9%
|
14.1%
|
17.3%
|
13.3%
|
13.9%
|
12.2%
|
12.9%
|
13.3%
|
ROA (Net income/ Total Assets)
|
7.43%
|
10.7%
|
8.85%
|
-
|
6.82%
|
6.36%
|
7%
|
7.57%
|
Assets
1 |
7,368
|
10,922
|
18,767
|
-
|
23,485
|
25,513
|
27,671
|
29,331
|
Book Value Per Share
2 |
4.350
|
4.960
|
5.670
|
5.790
|
7.030
|
7.760
|
8.780
|
9.940
|
Cash Flow per Share
2 |
0.5300
|
0.9200
|
1.130
|
1.200
|
1.540
|
1.390
|
1.630
|
1.810
|
Capex
1 |
751
|
1,313
|
2,091
|
2,947
|
2,848
|
2,661
|
2,236
|
2,666
|
Capex / Sales
|
19.99%
|
25.57%
|
28.09%
|
28.7%
|
24.68%
|
20.88%
|
15.47%
|
16.24%
|
Announcement Date
|
28/02/20
|
28/03/21
|
10/03/22
|
30/03/23
|
27/03/24
|
-
|
-
|
-
|
Last Close Price
19.3
CNY Average target price
22.71
CNY Spread / Average Target +17.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.40% | 4.17B | | +23.79% | 52.73B | | +37.49% | 39B | | -8.87% | 38.52B | | +28.34% | 30.38B | | -12.26% | 26.39B | | +10.41% | 26.08B | | +44.54% | 14.15B | | +32.22% | 12.6B | | -6.75% | 11.51B |
Other Biotechnology & Medical Research
|